Completed PHASE2 INTERVENTIONAL NCT00002919

Combination Chemotherapy in Treating Patients With Stage II Bladder Cancer

PHASE II TRIAL OF THE COMBINATION OF TRANSURETHRAL RESECTION AND NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH INVASIVE UROTHELIAL TRACT TUMORS SELECTED BY STAGE AND P53 NUCLEAR EXPRESSION

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Bladder Cancer

Interventions cisplatin conventional surgery doxorubicin hydrochloride filgrastim methotrexate vinblastine sulfate

Updated 5 times since 2017 Last updated: Jul 1, 2013 Started: Nov 30, 1996 Primary completion: Jan 31, 2003 Completion: Jan 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Bladder Cancer and is currently completed. Memorial Sloan Kettering Cancer Center leads this study, which shows 5 recorded versions since 1996 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 1996

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States